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Barcelona, located in North-Eastern 
Spain and on the shores of the Medi-
terranean, is one of the largest cities in 
Europe and the centre of a vast metro-
politan region of more than 160 towns 
with a total population of about 5 million 
people. It is the economic, cultural and 
administrative capital of Catalonia and 
the principal emerging area of economic 
activity in Southern Europe, with 17 mi-
llion people and 800,000 businesses. The 
Euro-Mediterranean region, including the 
Balearic Islands, Valencia, Aragon and 
South Eastern France, is primarily spe-
cialising in new strategically competitive 
international sectors, whilst consolidating 
its position internationally as one of 
Europe’s major regions.
We can find the basis of economic 
growth in metropolises with a poly-
centric and economically diversified 
business structure that facilitates and 
helps incubate new ideas, products and 
companies.
Taking into account the distribution of 
gross value added across business activi-
ties, Catalonia is Spain’s top autonomous 
region in the industrial sector, accounting 
for 25.2% of the total market. In terms of 
services, it is positioned second regarding 
national gross value added generated 
(19.5% of total). Catalonia accounts for 
28.2% of all Spain’s companies in indus-
tries with high and medium high-tech and 
knowledge-based services. 
Moreover, the rate of entrepreneurial 
activity in Catalonia in 2010 was 5.5%, 
higher than the Spanish and European 
averages, according to the Global Entre-
preneurship Monitor (GEM) 2010.
Barcelona’s international economic 
activities are mainly driven by the Trade 
Fair, the Port, Airport, the Zona Franca 
Consortium, Barcelona’s Tourism Consor-
tium, Barcelona City Council and its new 
technological innovation districts. As such, 
and given the importance of innovation 
in fostering competitiveness, productivity 
and the internationalisation of companies, 
the biotechnology sector is one of the key 
sectors for Barcelona and Catalonia.
Catalonia’s bio cluster is one the most 
dynamic in Spain, which overall happens 
to be one of the most active areas in 
southern Europe in this field. And it is es-
pecially active in clinical research and the 
human health care field, with 90 research 
centres and more than 400 consoli-
dated research groups engaged in the 
field of life sciences; excelling in areas 
such as oncology, bio nano-medicine 
and cardiovascular disease. Catalonia 
also boasts trained specialists that are 
highly prepared for the future. Of the 
twelve universities located on Catalan 
territory, five offer bioscience studies 
and over 24,000 students have already 
undergone training here.
22% of Spain’s biotech companies are lo-
cated in Catalonia; while 45% of Spain’s 
pharmaceutical companies are based in 
Catalonia, including the largest in the sec-
tor, which happen to all be Catalan firms: 
Almirall, Esteve Ferrer, Grifols, Lacer and 
Uriach. The Spanish pharmaceutical sec-
tor is Europe’s seventh biggest in terms 
of production volume.
In the last five years, according to the 
2011 Biocat Report, over 450 Catalan 
companies (biotechnology, pharma-
ceutical, medical technology innovators 
and service sectors) have experienced 
fluctuating growth rates between 15% 
and 30%, which, given the current 


















































10 reasons to invest 
in the biotechnology 
sector Catalan
Barcelona offers a va-
riety of characteristics 
that make it an attractive 
place to live, work and 
do business. The biote-
chnology and biomedical 
sector is one of the most 
dynamic, offering some 
of the best investment 
opportunities.
 06. Skilled professionals prepared for the future 
Catalonia has more than 25,000 researchers (7% of the working population) based in 
900 research centres, and of these there are 430 dedicated to the area of life sciences and, 
on the other hand, 90 research centres dedicating around 50% of their work to the life scien-
ces area. Ten of Catalonia’s twelve universities –eight of these located in the metropolitan 
area around Barcelona- offer bioscience studies: 155 courses taught with 24,000 students 
(Biocat 2009 report). Two of Barcelona’s top four business schools -ESADE and IESE- are 
among the world’s best 25. In addition, Barcelona has 34 international schools.
 07. Excellent quality of life  
For the 14th year running, Barcelona boasts Europe’s best quality of life for employees*. It 
has a mild climate, sun, beaches, culture, splendid leisure time and arts programmes, a net-
work of 4,500 educational institutions, modern and accessible health system. It is easy to 
get around on the public transport system and boasts beautiful parks that surround the city. 
 08. Consolidated science parks and growth          projects  
The city of Barcelona has six biotechnology-related science and technology parks (Parc 
Científic Barcelona, Parc de Recerca Biomèdica de Barcelona, Parc Barcelona Nord, Parc 
de Recerca i Innovació de la UPC, Parc de Recerca de la UPF and 22@ Barcelona), in 
addition to those in the surrounding environment: Biopol (Hospitalet), Parc Tecnològic del 
Vallès and the Parc de Recerca de la UAB (Cerdanyola) and the newly created Parc de 
l’Alba (in the ALBA Synchrotron environment, also in Cerdanyola) and orbital 40 (Te-
rrassa). Lleida, girona, Tarragona, Reus, Manresa also have science parks with activities 
related to the sector.
 09. Unique research facilities  
The Mare Nostrum Supercomputer (Barcelona Supercomputing Center BSC), the Na-
tional Centre for genome Analysis (CNAg) and ALBA Synchrotron-CELLS are three of 
Europe’s benchmark research facilities that are located in Barcelona and its surrounds. 
BSC, supported by the governments of Catalonia and Spain, is currently developing the 
PRACE project, which is designed to provide Barcelona with one of the most powerful su-
percomputers in Europe in 2012, and this should help develop and enhance both scientific 
research centres and companies’ investigation.
 10. Unique public-private cooperation 
Barcelona City Council and the government of Catalonia are committed to creating a 
favourable business environment, with the success of traditional local public-private 
partnerships being a key to the transformation of Barcelona to date. 
*According to Cushman & Wakefield, European Cities Monitor 2011.
 01. Strategic Geographical Location
Two hours by road from France and one day by road from the major European 
cities. The gateway to southern Europe, Barcelona boasts a major port, airport, 
free trade zone, logistics parks, an international trade fair and a city centre all 
within a radius of five kilometres
 02. Extensive transport infrastructure 
With its network of highways connected with Europe, Barcelona has the fastest 
growing European airport, Spain’s top port and the largest container port in the 
Mediterranean; a comprehensive metro and bus network, and a high-speed train 
infrastructure that is due to connect directly to the TgV and European network in 
2013. 
 03. Barcelona, center of a large, dynamic        and diverse economic area  
The city of Barcelona and its metropolitan area have a total population of 5 million 
people. This city is the capital of Catalonia, one of the most dynamic regions of 
Spain, with 7.5 million inhabitants, located in the heart of the Mediterranean, a 
large economic area with 18 million inhabitants. Barcelona accounts for 30% 
of Catalonia’s gDP and has a growth rate of 1, 7% gDP per year (2008). It is 
Europe’s sixth biggest urban agglomeration and its fifth largest in terms of indus-
try density. Catalonia has nearly 7,000 businesses working in innovation related 
activities, most of which are located in Barcelona and its surrounding area. 
 04. Successful foreign investment and         recognized international positioning 
Sixth best city for business in Europe*, Barcelona has the most foreign inves-
tment in Catalonia, which in 2010 was 3.999 billion, or 36% of all production 
investment received by Spain. There are more than 3,400 foreign companies 
established in Catalonia, 90% of whom are located in the Barcelona area, which 
has established itself as a centre for multinationals’ European divisions. Its qua-
lity of life and human capital are among the most valued aspects of Barcelona 
by foreign companies already set up in the city and in various other international 
rankings.
 05. Leading position in the Spanish and        European biopharmaceutical market 
Catalonia is home to 22% of all biotech companies in Spain and 45% of its phar-
maceutical companies; the largest in the sector –all Catalonian- are: Almirall, Esteve 
Ferrer, grifols, Lacer and Uriach. The Spanish pharmaceutical sector is ranked 
seventh in Europe in terms of production volume. Catalonia also boasts 40% of 
Spain’s medical technology companies, responsible for 50% of all turnover in the 














































and Catalonia  
03
Biotechnology is a key sector 
in order to transform the 
region’s current economic 
model into a system based 
on the knowledge economy. 
The recession that began in 
2008 has shown the im-
portance of this particular 
sector, especially given the 
fact that traditional industries 
have suffered badly from the 
severe downturn. In 2010, 
the US biotechnology ranked 
second in terms of inves-
tment volume -behind the 
software industry- with nearly 
$ 4 billion (3% more than 
in 2009) and over 450 tran-
sactions closed. Emerging 
economies such as China or 
Brazil are also investing in 
these sectors, with particular 
emphasis on the industrial 
and agricultural applications 
of biotechnology.
Catalonia’s bio cluster is the most 
dynamic in Spain, a country which 
also happens to be one of the 
most active areas of southern Eu-
rope in this field. It has more than 
450 sector related companies 
(biotechnology, pharmaceutical, 
medical innovation technology and
services for the sector), with 
growth rates fluctuating between 
15% and 30% over the last 5 years, 
and its 90 research centres and 
over 400 research groups excel in 
areas such as oncology, cardio-
vascular disease or bio nano 
medicine. 
This document aims to set out the underlying features of the current 
and future biotechnology sector in Catalonia and Barcelona under 
10 strategic reasons why:
01 The presence of large domestic pharmaceutical companies and 
major international groups
02 Entrepreneurship and innovation in biotech and medical technolo-
gy companies
03 Network of leading hospitals engaged in research
04 Benchmark training and research centres in the life sciences field
05 Barcelona Science Park (PCB): where research and innovation 
meet, and the country’s first bio-incubator
06 Barcelona’s Biomedical Research Park (PRBB), a centre for 
leading research groups
07 Autonomous University of Barcelona’s Research Park (PRUAB): 
research institutes and a bio-incubator
08 Large hospital research centres: IDIBAPS IDIBELL and VHIR
09 Biocat, promoting the Bioregion of Catalonia
10 Active government support for the biotechnology world
 
We have, therefore, a sector that 
has huge potential for Barcelona 
and Catalonia, and that has strong 
points and resources associated 
with its industry, research institu-
tions and government support – all 






Type of Company in Catalonia’s 
BioRegió
Companies fully engaged in biotechnology  399
Companies partly involved in biotechnology  161
Companies that use biotechnology  535
Total biotechnology companies 1,095 
 
Number of biotechnology companies in Spain
Source: Asebio 2010






































































Biotechnology plays a lea-
ding role in the pharmaceuti-
cal sector, even to the extent 
that we talk about a conver-
gence of the two sectors. 
The presence of drugs in 
today’s markets that have a 
biotech origin is increasing 
significantly, bringing out 
new drugs that are more 
specific and effective with 
fewer side effects. 
The Spanish pharmaceutical 
industry is mainly concen-
trated in Catalonia, where 
45% of the sector’s labo-
ratories are located, along 
with 50% of production and 
80% of companies working 
in the fine chemicals sector. 
In fact, Catalonia is the country-
of-origin of Spain’s top six phar-
maceutical companies: Almirall, 
Esteve, Ferrer, Grífols, Lacer and 
Uriach. In 2008, these companies’ 
spending on R&D stood at 381 
million euros. This tradition, and 
their dynamic nature, has attrac-
ted major foreign investments: 
the Catalan region has about 70 
pharmaceutical companies and 
is home to five of the world’s top 
ten biopharmaceutical companies: 
Amgen, Novartis, Pfizer, Roche and 
Sanofi-Aventis.
The agrofoods business sector, with 
strong roots in Catalonia and with a 
huge growth potential, is also one 
of the main users of biotechnology, 
mainly in order to create more pro-
fitable crops or plants that provide 











The world’s main pharmaceutical groups’ 
profits, 2009 (in billions of $)
01  Pfizer  $45,448 
02  Sanofi-Aventis  $40,871 
03  Novartis  $38,455 
04  GlaxoSmithKline  $36,746 
05  AstraZeneca  $31,905 
06  Merck & Co.  $26,929 
07  Johnson & Johnson  $22,520 
08  Eli Lilly & Co.  $20,629 
09  Bristol-Myers Squibb  $18,808 
10 Abbott Laboratories  $16,486 
11  Takeda Chem. Ind.  $14,204
The world’s main pharmaceutical groups’ 
profits, 2009 (in billions of $)
01  Roche/Genentech  $36,017 
02  Amgen  $14,642  
03  Novo Nordisk  $9,566 
04  Merck Serono  $7,454 
05  Baxter BioScience  $5,573 
In bold type those with activity in Catalonia 
Source:  
IB09: Biocat report on the state of the biotechnology, biomedicine and medical 
technologies sector in Catalonia 2009” (www.biocat.cat/publicacions/informe).











































The 480 companies that cu-
rrently make up the Catalan 
biotechnology sector 
(91 entirely dedicated to 
biotechnology) were all set 
up after the year 2000.
 
In the last five years, biotechno-
logy has grown between 15% 
and 30%. AB Biotics (functional 
foods), Advancell (nanomedicine), 
Archivel Farma (therapeutic vacci-
ne against tuberculosis) , Bioglane 
(industrial biotechnology), Bioin-
genium (bioremediation), ERA 
Biotech (cell technology), Immu-
novative developments (drugs for 
inflammatory immune disorders) , 
Neurotech Pharma (multiple scle-
rosis) , Omnia molecular (anti-in-
fectives) and Oryzon (biomarkers) 
are just some examples.
What lies behind the growth of the 
biotechnology sector is talent and 
skilled human capital, and strong 
collaborative bonds between acade-
mia and business. Catalonia has  
12 universities with 177,000 degree 
and masters students, accounting 
for 12.5% of the whole Spanish 
university system (2009-10 data). 
Some 43,500 students were enro-
lled on postgraduate studies during 
this period.
Regarding business schools, which 
is often an indicator associated with 
entrepreneurship, Barcelona boasts 
two of the top twenty schools in the 
world: IESE and ESADE (according 
to the Financial Times 2011). In 
addition, in 2008 Barcelona was the 
third European city attracting most 
international MBA students, only 
beaten by Paris and London, accor-
ding to the aforesaid newspaper.
Catalonia accounts for one fifth 
(20.98%) of all Spain’s biotech 
companies, according to the latest 








of Biotechnology Companies 
in Spain). According the Biocat 
Report 2011, in Catalonia there 
are 480 companies involved in 
Catalonia’s biotech sector, of 
which 91 are principally engaged 
in biotechnology related business, 
71 are pharmaceuticals, 106 
are medical technology compa-
nies, 29 are in fine chemicals (a 
major sector for the development 
of active ingredients) , 45 are 
foodstuffs companies, 9 from the 
biocomputing area, and the rest 
are providing support services. 
Of those companies in the R+D 
area, 58.7% are working on red 
biotechnology (health); 47.1% in 
white biotechnology (industrial); 
and 28.1% in green tehnology 









































































In Catalonia, there is a 
unique form of interaction 
between hospitals, univer-
sities, research centres and 
industry in general, covering 
all areas from basic to clini-
cal research.
Catalonia stands out in the 
field of clinical research and 
human health research. It 
has a network of 215 hospi-
tals, 13 of which are develo-
ping outstanding research. 
Amongst them, six are 
amongst Spain’s top science 
research producers.
The Barcelona area has a large 
network of teaching hospitals too, 
among them Hospital Clínic Provincial 
de Barcelona, Hospital de Bellvitge, 
Hospital de la Vall d’Hebron, Hospital 
de la Santa Creu i Sant Pau, Hospital 
de Sant Joan de Déu, Hospital del Mar 
and Hospital Germans Trias i Pujol, all 
carrying out world leading research, 
ranging from basic research to advan-
ced diagnostic and clinical research.
One example is a Hospital Clínic 
research centre, the Centre for Inter-
national Health Research (CRESIB), 
which leads the worldwide develo-
pment of a vaccine against malaria, 
thanks to sponsorship by the Bill and 
Melinda Gates Foundation.
Barcelona and Catalonia enjoy an 
outstanding tradition in quality clinical 
trials. This region enjoys competitive 
advantages in this field because 
of the quality research that can be 
undertaken here, because of safety 
and research effectiveness in terms 
of patient selection and its compe-
titive pricing structure. Over the last 
10 years, the Catalan public health 
system has increased its research 
trials by 95%, making Catalonia the 
leading region in Spain in terms of 
percentage points (52.4%), mainly in 
phase II and III trials.
The private and public sectors work 
closely together. There are nume-
rous cases of collaboration, and 
these days hospitals themselves 
are starting their own entrepreneu-
rial projects. Catalonia has seen a 
number of companies that have set 
up and become highly successful 
across various therapeutic areas. 
There is a sub-sector of services 
companies of about 30 CRO (con-
tract research organizations) that 
contribute to the development and 








CIBEK, a patronage initiative in Barcelona

















































mechanisms and work on applica-
tions for these cells in the treatment 
of degenerative diseases.
Centre for International Health 
Research (CRESIB)
CRESIB researches issues related 
to the new international health cha-
llenges we face in the twenty-first 
century. Since May 2010, CRESIB 
has been part of the Barcelona Glo-
bal Health Institute (ISGLOBAL). 
National Centre for Genome 
Analysis (CNAG)
This centre is dedicated to the 
study of sequencing, analysis 
and interpretation of information 
contained in organisms’ genomes. 
10 years after the publication of the 
first human genome sequence after 
decades of research, CNAG can 
now sequence in just a day.  
Centre for Genomic 
Regulation (CRG)
One of the main areas of excellence 
that Barcelona boasts is research 
is related to this centre. At CRG 
they carry out basic research in 
biomedicine, especially in the areas 
of genomics and proteomics. Its 
researchers and group leaders are 
recruited and evaluated internatio-
nally, ensuring the highest scientific 
levels. 
Catalonian Institute of 
Bioengineering (IBEC)
IBEC carries out research into bioen-
gineering all the way from its most 
basic level up to medical applica-
tions; it has become an international 
benchmark in this field. Its location in 
the Barcelona Science Park (PCB) 
means it can keep up with this highly 
dynamic area of life sciences. 
Catalan Institute of 
Cardiovascular Sciences (ICCC)
ICCC is located in the Hospital de 
la Santa Creu i Sant Pau in Barce-
lona, and it conducts research on 
cardiovascular and heart disease, 
competing at the highest internatio-
nal level. The centre has been highly 
successful at transferring research 
into therapeutic developments and 
diagnostics.
Institute of Biomedical 
Research (IRB)
Founded in 2005 and located in 
Barcelona’s Science Park (PCB),  
IRB is dedicated to basic and 
applied biomedical research. Highly 
dynamic and working to the highest 
international levels of excellence, 
some of its main achievements 
have been in the area of cancer 
research.
Institute for AIDS Research 
(IrsiCaixa)
It works to develop knowledge, 
prevention and treatment of HIV 
infection and AIDS, with the ultimate 
goal of eradicating this disease. 
Located in the University Hospital 
Germans Trias i Pujol in Badalona, 
it conducts research in partnership 
with Barcelona’s Hospital Clínic.
ALBA Synchrotron
Alba is a new generation synchro-
tron located near the Autonomous 
University of Barcelona. The 
synchrotron and the nearby new 
Parc de l’Alba facilities have been 
equipped to host researchers from 
around the world that use X-ray 
analysis on their samples. 
Vall d’Hebron Institute of 
Oncology (VHIO)
Recent years have seen key 
findings emerge on the molecular 
basis of cancer, and this has led 
to new and better treatments for 
this disease. VHIO is working along 
similar research lines, providing a 
common space for scientists and 
doctors working on basic science 
and clinical research. 
The growth and development of the 
biotechnology industry in Catalo-
nia is possible because there is an 
adequate supply of science and te-
chnology parks suitable for business 
incubation during their early stages 
of creation. Of Catalonia’s 17 parks, 
13 are actively involved in biotech-
nology and biomedicine. In addition 
to providing science and technology 
facilities, offices and laboratories, 
these parks provide a meeting 
point for research, innovation and 
companies, as well as a competitive 
environment, and support services 
to help grow business projects while 
also providing access to experts in 
intellectual property and investors.
Catalonia has 430 research 
groups and 90 recognized 
research centres that are 
developing activities in the 
life sciences field.    
In Catalonia, training in life scien-
ces and healthcare in general has 
increased considerably in recent 
years, both at universities and 
business schools in order to meet 
the needs of a sector that is emer-
ging as a major economic driver 
for the country. Ten of Catalonia’s 
twelve universities teach studies 
related to this area, although the 
University of Barcelona (UB), 
the Autonomous University of 
Barcelona (UAB) and the Po-
lytechnic University of Catalonia 
(UPC) account for almost 60% of 
the training given in this field. The 
number of students enrolled on 
these courses is nearly 25,000.
Bioscience research is carried out 
at 10 universities, with 25,000 
researchers generating 25% of all 
Spain’s scientific output and 57% 
of its biomedicine publications*. 
One important figure that shows 
the degree of research speciali-
zation in Catalonia is the fact that 
over 60% of centres do research 
on human health, and over 70% of 
all researchers working in the field 
of genomic science in Spain do so 
in research centres in Catalonia.
Barcelona Supercomputing 
Center (BSC)
Located in the emblematic Torre 
Girona building in Barcelona, the 
BSC-CNS (Barcelona Supercompu-
ting Center) is Spain’s National Su-
percomputing Center that plays host 
to the Mare Nostrum supercomputer, 
one of the most powerful in Europe. 
Centre for Regenerative Medici-
ne in Barcelona (CMR)
CMR is located in the Barcelona 
Biomedical Research Park (PRBB) 
and principally researches human 
embryonic stem cells to unders-
















Science and technology parks
















































Science parks are catalysts 
for regional economic 
development and facilitate 
the creation and growth 
of new technology-based 
companies, promoting 
knowledge transfer from 
universities to industry.
Barcelona Science Park (PCB) is a 
recognised successful model. This 
is the largest business incubator in 
Catalonia and it produced the first 
Catalan biotechnology company in 
2009; the Park also plays host the 
latest science facility to be opened 
in our country, the National Centre 
for Genome Analysis (CNAG), which 
together creates an innovation area 
that currently occupies 60,000 m2. 
PCB houses 75 companies, 
9 technology platforms, 36 technical 
units, 4 research institutes and 
70 research groups. It also organi-
zes more than 120 activities a year 
in order to promote a culture and 
vocation for science, which involves 
close to 6,000 people.
Founded by the University of 
Barcelona in 1997, this was the 
first science park to open in Spain. 
These days it is regarded as a 
benchmark for the international 
promotion of innovation with over 
2,200 employees. It is a model 
for the creation and growth of 
biotech SMEs and has contributed 
hugely to a new innovation-based 
economy.
One of its main values is its own 
internal triple helix model (public 
administration, business and uni-
versity), which is a key to compe-
titiveness in this sector with public 
and private research and techno-
logy platforms. Within this same 
space we find companies, techno-
logy platforms and research groups 
which enjoy full access to a wide 
range of science and technology 
support services.
Setting up the National Centre for 
Genome Analysis (CNAG) within 
the Barcelona Science Park (PCB) 
–which happens to be Catalonia 
and Spain’s newest facility– 
reflects the excellent results 
achieved so far and its role as a 
driving force in this area.
The Barcelona Biomedi-
cal Research Park (PRBB) 
occupies 55,000 m2 on the 
city’s shoreline overlooking 
beaches and next to Hos-
pital del Mar in the 22@ 
area. Here we find scientific 
experts, some working on 
molecular analysis, others 
in terms of the population 
perspective. PRBB has 
become one of the leading 
biomedical research centres 
in southern Europe. 
Created in 2002 by the UPF, the 
Autonomous Regional Government 
of Catalonia and Barcelona City 
Council, its expansion process en-
ded in late 2005 and now employs 
over 1,300 people, the majority of 
these foreigners (covering 50 diffe-
rent nationalities).
The scientific activities of research 
groups that are working here 
are grouped under the areas of 
biomedical computing and the 
biology of systems, epigenetics and 
gene regulation, cell biology and 
its development, pharmacology, 
pathophysiology and clinical human 
genetics and evolutionary biology, 
epidemiology and public health.
The Park has also produced busi-
ness initiatives like the start-up qGe-
nomics and Chemotargets based on 
science initiatives.
Barcelona Biomedical Research 
Park (PRBB) has 8 institutes and 
independent research centres 
that have achieved excellence in 
their fields, all focused on different 
aspects of biomedicine. 
- Municipal Institute of Medical 
Research (IMIM)
- Centre for Genomic Regulation 
(CRG)
- Institute of Advanced Technology 
(IAT)
- Centre for Regenerative Medicine 
in Barcelona (CMR)
- Centre for Research in Environ-
mental Epidemiology (CREAL)
- Pompeu Fabra University’s De-
partment of Experimental and Health 
Sciences (CEXS-UPF)
- Pasqual Maragall Foundation (FPM)
- IBE - Institute of Evolutionary Biolo-
gy (CSIC-UPF)
PRBB also offers four technology 
service platforms, including the Cata-


















The National Centre for Genome Analysis is one of the most 
important centres for sequencing and molecular research in Europe




























The UAB Research Park’s tech-
nology transfer services, and its 
scientific and technical services are 
available to researchers at the UAB, 
CSIC and IRTA related centres and 
institutes as well as other centres 
and institutes that make up the 
UAB Research Park, besides the 
university’s own research groups. 
Companies located in the Park and 
those that have come about from 
Park-related projects like start-ups 
or spin-offs can also make the most 
of these services.
The Autonomous University 
of Barcelona’s Research 
Park (PRUAB) is one of 
Catalonia and Spain’s most 
important business, industry 
and knowledge generators.   
The UAB Research Park was set 
up in late 2007 by three leading 
research institutions: the UAB, the 
Council for Scientific Research 
(CSIC) and the Institute for Re-
search and Technology (IRTA) in 
order to foster, promote and impro-
ve the transfer of knowledge and 
technology between universities 
and companies.
In addition to the UAB’s own 
departments and research groups, 
the Park has numerous centres and 
institutes located on its Bellaterra 
Campus and at the Torre Mari-
mon Farm (Caldes de Montbui). 
They all carry out research in five 
main themes: Biotechnology and 
Biomedicine, Health and Animal 
Production, Processing of Food  
and Food Safety, Health and Beha-
vioural Sciences, Social Sciences 
and Humanities and Science and 
Technology.
 
Currently, the UAB Research Park 
has 30 research centres and insti-
tutes and more than 4,000 resear-
chers. In 2006 it registered  
60 patents and generated funds 
worth 68 million euros.
PRUAB has 14 small and medium 
sized companies located there in 































PRUAB Research Centres and 
Institutes working in fields 
related to biotechnology and 
biomedicine include:
- CBATEG: Centre for Ani-
mal Biotechnology and Gene 
Therapy
- CRAG: Agrogenomics Re-
search Centre 
- IBB: Institute of Biotechnology 
and Biomedicine
- INc: Institute of Neuroscience
- LP CSIC-UAB: CSIC-UAB 
Laboratory of Proteomics
- ALBA Synchrotron
- Centre for Research in Na-
noscience and Nanotechnology 
(CIN2)
ALBA Synchrotron


















































pitals have a long tradition 
bringing together excellence 
in health care, training and 
basic and related research. 
This can be seen by the fact 
that Barcelona’s principal 
hospitals all have their own 
research institutes. 
In Barcelona and its surrounds there are 
six hospital research institutes, five of 
which - Vall d’Hebron Researh Institute 
(VHIR), Bellvitge Biomedical Research 
Institute (IDIBELL), Health Sciences 
Research Institute of the “Germans 
Trias i Pujol”  Foundation (IGTP), August 
Pi i Sunyer Biomedical Research 
Institute (IDIBAPS) and Sant Pau 
Biomedical Research Institute (IIB Sant 
Pau)— are certified as medical research 
institutes by the Ministry of Science and 
Innovation, a quality stamp awarded 
by the Instituto de Salud Carlos III, a 
state support agency for research that 
provides accreditation for institutes and 
networks and focuses research on set 
objectives, a mission that only one other 
hospital in Spain, the Virgen del Rocío 
de Sevilla, has.
Research institutes in 
Barcelona’s hospital system 
August Pi i Sunyer Biomedical 
Research Institute (IDIBAPS)
IDIBAPS’ research focuses on six 
main investigation lines and it aims to 
integrate quality clinical research with 
high quality basic research through its 
60-or-so research teams. 
Bellvitge Biomedical Research 
Institute (IDIBELL)
IDIBELL is a stem cell medical 
research centre, including the par-
ticipation of the University Hospital 
of Bellvitge, the Catalan Institute of 
Oncology, the University of Barce-
lona and the Institute of Diagnostic 
Imaging. The Institute is part of 
Hospitalet’s Biopol’H health care 
research park.
Vall d’Hebron Researh 
Institute (VHIR))
VHIR is a biomedical research centre 
working in the fields of diagnostics, 
therapeutics and the treatment of 
problems related to healthcare issues. 
Besides this, the Institute is highly 
committed to supporting entrepreneu-
rial business ventures that arise from 
their research programmes. 
The Sant Pau Biomedical 
Research Institute (IIB Sant Pau) 
The Sant Pau Institute for Biome-
dical Research carries out medical 
research into basic, clinical, and 
epidemiological health care issues, 
and their investigation lines come 
together in 10 of the highest quality 
research entities. Occupying 6,000 m2 
of space, the shared research facili-
ties play host to more than 400 basic 
scientists and clinicians grouped in 
7 areas of research.
Municipal Institute of Medical 
Research (IMIM) 
The Research Institute of the Hospital 
del Mar forms a part of the Pompeu 
Fabra University (UPF) and boasts 
350 researchers. Their research is 
divided into five programme areas: 
cancer, epidemiology and public 
health, inflammation and cardiovas-









ThE BiorEGion of 
CaTaLonia
Created in 2006 thanks to the Gover-
nment of Catalonia and Barcelona City 
Council, Biocat’s foundation gover-
nance structure includes extensive re-
presentation from the biomedical and 
biotechnology sector, as well as the 
Administration, universities, research 
companies and support organizations.
Biocat promotes collaboration bet-
ween biocluster stakeholders and a 
variety of other entities both inside and 
outside of Catalonia, at the national 
and international level. It offers flexible 
and innovative solutions to challenges 
facing the sector, always pursuing the 
highest quality and efficiency. The Bio-
cat action plan has a clear customer 
focus, reflecting a strong commitment 
to its goals and people in general.
Its action plan is divided into five 
strategic priorities:
- Consolidation of Catalonia’s 
biocluster
- Promoting business competiti-
veness
- Internationalization
- Training and attracting talent
- Generating a positive social 
perception of biotechnology
To achieve its goals in the above 
stated five priority areas, it has 
designed tailor made programmes 
that address the needs and specifi-
cities of the sector, offering a range 
of services that run from training 
programmes to the publishing of 
industry reports, organizing sector 
meetings and providing support 
in the internationalization process, 
and even personalized advice for 
companies, project start-ups or the 
design of sector relevant strategic 
initiatives.
Biocat, along with the City Coun-
cil, drives the city’s international 
promotion as a place for biotech-
nology companies to set up via the 
Barcelona Biotech brand and it also 
establishes partnerships with coun-
terpart institutions and stakeholders 
in the main international markets 
of interest to promote exchanges 
and cooperation between sector 
members.
More information from  
www.biocat.cat 
 
Biocat is an entity that 
coordinates and promotes 
innovation into biotechnolo-
gy, biomedicine and medi-
cal technology in Catalonia. 
Its mission is to promote 
and energize stakeholders 
operating in this sector and 
develop related initiatives 
in order to create the right 
environment for a powerful 
research system to flourish. 
Other objectives include 
helping to create active 
knowledge transfers and an 
entrepreneurial business 
network so that this sector 
can become an economic 
driver for the country and 
also so that it contributes 
to the overall welfare of 
society.
Over 600 representatives of Catalonia’s biotech sector meet every year for the Biocat Forum

















































Over the last 20 years, 
Public Administrations in 
Catalonia, Spain and Eu-
rope have made serious 
commitments to promoting 
science and technology, by 
investing in universities, re-
search centres, talent, entre-
preneurship, science parks 
and technology platforms   
Barcelona City Council has been 
promoting innovation in biotech-
nology via a series of action plans: 
through its development agency, 
Barcelona Activa, via initiatives 
created by its innovation district, 
22@Barcelona, and through its 
employment support programmes at 
Porta 22, besides the coordinated 
actions of its management at the 
Council’s Department of Economics, 
Business and Employment. These 
are aimed at highlighting the value 
of science and Catalan innovation 
while promoting the creation and 
growth of companies involved in 
biotechnology, biomedicine and 
medical technology.
Investment in biotechnology, 
whether it comes from the Spanish 
Government, the Autonomous Re-
gional Government or the European 
administrations, has grown at a 
significant rate with incentives for 
research, training and recruitment.
In Catalonia, spending on internal 
R&D has grown at around 12% 
on average per year, rising from 
2.107 bn € in 2004 to 3.286 bn € 
in 2008, which represents 1.61% 
of GDP (data published in 2010). 
The Autonomous Regional Go-
vernment finances the sector via 
its Department of Economics and 
Knowledge, the Department of 
Business Enterprise and Emplo-
yment, and the Health and Edu-
cation Departments. For example, 
there are a number of program-
mes regarding financing options: 
AGAUR programmes (Agency for 
the Management of University and 
Research Grants), the SGR call for 
consolidated research groups, or 
ACC1Ó programmes (Catalan trade 




SUpporT for ThE 
BioTEChnoLoGy 
worLd 
businesses a number of financing 
alternatives like risk capital lines, 
loans, guarantees, share swop loans, 
subsidies and tax incentives for 
R&D…). In 2009 ACC1Ó spent up 
to 6.7 million euros on this sector: 
a million euros on research centre 
projects, 4.1 million in grants for 
R&D in pharmaceutical, biotech 
and medical technology companies 
and the rest on support structures 
(2009).
The Catalan government also 
supports investment in Catalonia via 
its Invest in Catalonia agency, which 
offers services to companies with 
solid and stable investment projects. 
These services include help and 
assistance at different levels and 
advice on incentives and financing, 
or re-investment, or capital expan-
sions, etc..
Meanwhile, the Catalan Institute of 
Finance has placed 27 million euros 
in venture capital funds that invest 
exclusively or partially in this sector.
At the state level, we have grants 
like Neotec, Profit, Torres Quevedo, 
Cenit, Consolidar and Ciber, the 
financing of Genoma España and 
subsidies from ICEX to business 
associations in the sector. One of 
the latest programmes is the sub-
programme Severo Ochoa that is 
designed to encourage research 
excellence in Spanish State uni-
versity departments or institutes, 
foundations, and centres, institutes 
and public agencies.
As regards talent, one highly notable 
example of support measures is the 
Autonomous Regional Government 
of Catalonia’s ICREA programme, 
which has hired 250 researchers in 
different areas, with 31% of these 
working in the field of life sciences 
and health sciences.
Within each community, council, 
university, hospital, etc., we can 
find institutions and development 
agencies (in Catalonia, ACC1Ó 
and Barcelona Activa), evaluation, 
technology transfer and entrepre-
neurship entities (like OTRI, eva-
luation structures of research done 
in hospitals and universities, and 
technology springboards, etc..) that 
are developing the consolidation of 
knowledge in biosciences. These 
are promoting the sector –along 
with the coordinated support and 
promotional zeal of the biocluster 
management team (Biocat)-, so as 
to create a true driver of the eco-
nomy and an opportunity to make 
the quality of life of society better.




















































ACC1Ó-generalitat de Catalunya 
(Catalan government)
www.acc10.cat
Management Agency of University and 
Research grants (AgAUR) 
www.gencat.cat/agaur
Department of Economics, Business 














Centre for Biomedical Research 
Esther Koplowitz (CIBEK)  
www.cibek.org
Research Center for Nanoscience and 
Nanotechnology (CINC2)  
www.cin2.es
Centre for Animal Biotechnology and 
gene Therapy (CBATEg) 
www.cbateg.net (under construction)
Centre for Regenerative Medicine in 
Barcelona (CMRB) 
www.cmrbarcelona.eu 
Centre for Research in Agricultural 
genomics 
www.cragenomica.es
Centre for Research in Environmental 
Epidemiology (CREAL)  
www.creal.cat
Barcelona Centre for International 
Health Research (CRESIB)  
www.cresib.cat
Centre for genomic Regulation (CRg) 
www.crg.es
National Centre for genome 
Analysis (CNAg)  
www.cnag.cat
Higher Research Council (CSIC)
www.dicat.csic.es












Hospital de la Vall d’Hebron 
www.vhebron.net 
Hospital de Sant Joan de Déu 
www.hsjdbcn.org
Hospital del Mar (IMAS)
www.parcdesalutmar.cat/hospitals/
hospital-del-mar
Hospital Universitari de Bellvitge 
www.bellvitgehospital.cat
Hospital Universitari germans 
Trias i Pujol 
www.gencat.cat/ics/germanstrias
IESE Business School 
www.iese.edu
 
Catalan Institute for Research and 
Advanced Studies (ICREA) 
www.icrea.cat
Catalan Institute of Cardiovascular 
Sciences (ICCC)  
www.iccc.cat
 
Catalan Institute of Finance  
www.icfinances.com
Institute of High Technology 
(IAT) 
www.crccorp.es
Bellvitge Biomedical Research 
Institute (IDIBELL) 
www.idibell.cat
Biomedical Research Institute 
at Sant Pau Hospital (Sant Pau 
IIB) 
www.iibsantpau.cat
Vall d’Hebron Institute of oncology 
(VHIo) 
www.vhio.net
Institute for Bioengineering of 
Catalonia (IBEC) 
www.ibecbarcelona.eu
Barcelona Institute of Molecular 
Biology (IBMB) 
www.ibmb.csic.es 
Institute of Biotechnology and 
Biomedicine (IBB) 
http://ibb.uab.es
Institute of Neuroscience  
http://inc.uab.cat
Barcelona Institute for Biomedical 
Research (IRB) 
www.irbbarcelona.org 
The AIDS Research Institute 
(IrsiCaixa)
www.irsicaixa.org
Institute for Research and 
Technology (IRTA) 
www.irta.es
global Health Institute of Barcelona 
(ISgLoBAL) 
www.isglobal.es
August Pi i Sunyer Institute of 
Biomedical Research (IDIBAPS)
www.idibaps.org
Institut Municipal d’Investigació 
Mèdica (IMIM) 
www.imim.es 
Carlos III Health Institute 
www.isciii.es
Laboratory of Proteomics CSIC-UAB 
(LPCSIC-UAB)
http://proteomica.uab.cat
Barcelona Science Park (PCB) 
www.pcb.ub.edu
 
Parc de l’Alba 
www.parcdelalba.com









Vall d’Hebron Research Institute 
(VHIR)  
www.ir.vhebron.net
www.bcn.cat/barcelonabusiness
With co-financing
